Sorafenib for the Treatment of Alcohol-Related Hepatocellular Carcinoma (HCC): Subanalysis of the Phase III SHARP Trial

被引：0

作者：

Trojan, J. ^{[1
]}

Craxi, A. ^{[2
]}

Porta, C. ^{[3
]}

Sangiovanni, A. ^{[4
]}

Shan, M. ^{[7
]}

Nadel, A. ^{[7
]}

Voliotis, D. ^{[7
]}

Bruix, J. ^{[5
]}

Llovet, J. ^{[5
,6
]}

机构：

[1] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Frankfurt, Germany

[2] Azienda Osped Univ, Unita Operat Complessa Gastroenterol & Epatol, Palermo, Italy

[3] IRCCS San Matteo Univ Hosp, Pavia, Italy

[4] Univ Milan, Milan, Italy

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Mt Sinai Sch Med, New York, NY USA

[7] Bayer HealthCare Pharmaceut, Montville, NJ USA

来源：

ONKOLOGIE | 2010年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：84 / 84

页数：1

共 50 条

[1] SORAFENIB FOR THE TREATMENT OF ALCOHOL-RELATED HEPATOCELLULAR CARCINOMA (HCC): SUB-ANALYSIS OF THE PHASE III SHARP TRIAL
Craxi, Antonio
Porta, Camillo
Sangiovanni, Angelo
Shan, Minghua
Nadel, Andrea
Voliotis, Dimitris
Bruix, Jordi
Llovet, Josep M.
HEPATOLOGY, 2008, 48 (04) : 971A - 971A
[2] Sorafenib in the treatment of advanced Hepatocellular Carcinoma (HCC) -: Experiences beyond the sharp trial
Woerns, M.-A.
Schulze-Bergkamen, W.
Schuchmann, M.
Otto, G.
Galle, P. R.
Weinmann, A.
ONKOLOGIE, 2008, 31 : 80 - 80
[3] Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial
Craxi, A.
Porta, C.
Sangiovanni, A.
Seitz, J.
Moscovici, M.
Shan, M.
Nadel, A.
Voliotis, D.
Bruix, J.
Llovet, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik-Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han Chong
Gorbunova, Vera
Eskens, Ferry
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El Nowiem, Saied
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[5] Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial
Raoul, J.
Craxi, A.
Porta, C.
Lentini, G.
Nadel, A.
Voliotis, D.
Bruix, J.
Llovet, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Llovet, J.
Ricci, S.
Mazzaferro, V.
Hilgard, P.
Raoul, J.
Zeuzem, S.
Poulin-Costello, M.
Moscovici, M.
Voliotis, D.
Bruix, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)
Cheng, A.
Kang, Y.
Lin, D.
Park, J.
Kudo, M.
Qin, S.
Omata, M.
Lowenthal, S. W. Pitman
Lanzalone, S.
Yang, L.
Lechuga, M.
Raymond, E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE
Bruix, J.
Raoul, J. L.
Sherman, M.
Shan, M.
Lentini, G.
Nadel, A.
Voliotis, D.
Llovet, J. M.
JOURNAL OF HEPATOLOGY, 2009, 50 : S28 - S29
[9] Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
Rimassa, Lorenza
Santoro, Armando
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 739 - 745
[10] Clinical features of alcohol-related hepatocellular carcinoma (HCC) in Italy: a multicenter prospective survey
Rossini, Angelo
Sacco, Rodolfo
Fornari, Fabio
de Sio, Ilario
Spinzi, Giancarlo
Francica, Giampiero
Parisi, Giancarlo
Salmi, Andrea
Dionigi, Elena
Farinati, Fabio
Di Fonzo, Michela
Salvagnini, Mario
Vicari, Susanna
Borzio, Mauro
HEPATOLOGY, 2012, 56 : 453A - 454A

← 1 2 3 4 5 →